Novel Immunological Markers of Lyme Borreliosis
Year: 2014
Type: dissertation
Study design: Observational Study
Abstract: Lyme borreliosis (LB) is a bacterial infection spread by the bite of Ixodes sp. ticks. Borrelia burgdorferi sensu lato group of spirochaetes is causing the infection. Less than 10 species are known to be pathogenic to humans. Distribution of B. burgdorferi sensu lato species varies geographically and LB is endemic in Europe, Asia and North America. The typical initial manifestation of LB is a ring-like rash, erythema migrans (EM). EM appears around the tick bite site after a couple of days or weeks. Diagnosis of LB is based on EM and the infection is treated with antibiotics. In some cases, the tick bite or EM may go unnoticed. Manifestations of late-stage LB are Lyme arthritis, cardiac symptoms, neuroborreliosis (LNB) manifesting as meningoradiculitis or meningitis, or chronic atrophic skin changes (acrodermatitis chronica atrophicans). These late-stage manifestations may appear within weeks, months, or in rare occasions after years. Frequently, laboratory tests are needed to confirm the clinical diagnosis. Laboratory testing is mainly based on the detection of Borrelia specific antibodies, usually with ELISA method or immunoblotting. There are no markers of active LB and antibody responses may persist for years after the treatment of the infection. The aim of this study was to identify new immunological markers for the laboratory diagnostics of LB. A large amount of serum and cerebrospinal fluid (CSF) samples were collected from patients with different manifestations of LB from Europe and the United States. Five peptide variants of IR6 (= invariable region 6 of the VlsE protein) as antigens were compared to commercial C6 Immunoassay in the serodiagnosis of early and disseminated stages of LNB. Recombinant decorin binding proteins A (DbpA) and B (DbpB) (three variants of each) as antigens were evaluated in the serodiagnosis of LNB. CXCL13 Immunoassay was used to measure chemokine CXCL13 levels in children with early LNB. As a conclusion, the use of a combination of different IR6 peptide variants in one assay may improve the laboratory diagnostics of LB by increasing the sensitivity of the test. DbpA and DbpB may serve as supplementary antigens in diagnostic assays. Appearance of CXCL13 in the CSF seems to be an early immunological marker of inflammation in CNS. Measurement of CXCL13 concentrations in the CSF may improve the diagnostics of LNB.
Author: Heidi Sillanpää
Language: English
Subfield: Parasitology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Funder: Biomedicum Helsinki-säätiö
OpenAlex ID: W1529562077
